Nicergolina LPH is a drug that supports management of certain conditions related to blood circulation and cognitive function. It contains the active substance nicergoline, a semisynthetic ergot derivative.

Quick Facts

• May be considered for the symptomatic management of chronic pathological cognitive and neurosensorial impairment, excluding cases of Alzheimer's disease and other specific dementias.
• Used as an adjunctive treatment for intermittent claudication associated with symptomatic peripheral arterial occlusive disease (PAOD, Stage II).
• May be used to assist in the management of Raynaud's syndrome.
• Considered for ancillary treatment of certain disturbances of visual acuity and visual field that may be of vascular origin.
• Applied in the management of acute retinopathies that are vascular in nature.
• Employed for the prophylaxis (prevention) of migraine headaches.

---

Nicergolina LPH is primarily indicated for addressing symptoms in individuals experiencing chronic cognitive and neurosensorial impairment associated with older age. This is distinct from the primary management of Alzheimer's disease or other forms of dementia.

The medication is also utilised as a supporting option for conditions involving impaired peripheral blood flow, such as intermittent claudication—where pain arises in the legs during walking due to arterial obstruction—and Raynaud's syndrome. Furthermore, its therapeutic scope includes assisting in the management of vascular-related issues affecting the eyes, such as acute retinopathies, and as a preventive measure for migraine headaches.

Eligibility and Non-Eligibility for Nicergolina LPH

Official regulatory information strictly defines who may or may not use Nicergolina LPH (nicergoline) based on specific clinical and physiological states. This medicine is contraindicated and must not be used in individuals who meet any of the following non-eligibility criteria:

• Hypersensitivity: Patients with known allergy or hypersensitivity to the active substance nicergoline, to any other ergot derivatives, or to the product's excipients.
• Acute Cardiovascular Conditions: Individuals experiencing acute bleeding, those with a history of recent myocardial infarction (heart attack), or patients with severe bradycardia (abnormally slow heart rate).
• Hypotension: Patients with existing hypotension (low blood pressure) or a marked tendency toward it, such as orthostatic hypotension (dizziness upon standing).
• Reproductive Status: The medicine is contraindicated for women who are pregnant or breastfeeding.

Restricted Eligibility

• Age-Related: Use is not recommended in children and adolescents under 18 years of age, as safety and efficacy have not been established in this population.
• Renal Function: Patients with impaired renal function require special consideration, and a dose reduction is generally recommended as a regulatory precaution.

Official Interactions with other medicines and products

The official regulatory profile for Nicergolina LPH documents several clinically relevant interaction patterns, primarily categorized as pharmacodynamic and pharmacokinetic effects.

Pharmacodynamic Interactions Co-administration with Antihypertensive Agents may lead to a potentiation of the hypotensive effect, increasing the risk of excessively low blood pressure. Due to Nicergolina LPH’s intrinsic antiplatelet properties, concomitant use with Anticoagulants (such as Warfarin) or Antiplatelet Agents (such as Aspirin) increases the risk of hemorrhage or bleeding. Caution is also required with Beta-Blocking Agents, as their cardiac depressant effects may be potentiated. Nicergolina LPH may also antagonize the vasoconstrictor effects of co-administered Sympathomimetic Drugs.

Pharmacokinetic and Clearance Notes Nicergoline metabolism is affected by the Cytochrome P450 (CYP) enzyme system. Co-administration with potent CYP Enzyme Inhibitors can decrease clearance and result in an increased plasma concentration of Nicergoline. Furthermore, regulatory documentation notes that patients with Renal Impairment may experience reduced clearance of metabolites, which influences interaction risk.

Other Documented Cautions Caution is required when co-administering with Alcohol due to the potential for enhanced central nervous system effects, such as dizziness. An interaction concern also exists with drugs that affect uric acid metabolism, as Nicergolina LPH may increase serum uric acid levels.

Modulation of Vascular Tone and Microcirculation

Nicergoline acts as an Alpha-1 (alpha1) Adrenergic Receptor Antagonist, selectively binding to and blocking these receptors on the smooth muscle of blood vessels, particularly in the microcirculation. This blockade reduces vasoconstrictive signaling by endogenous catecholamines. The physiological consequence is a reduction in peripheral and cerebral vascular resistance, which leads to increased arterial blood flow and enhanced circulatory dynamics.

Influence on Cerebral Metabolism and Neuronal Pathways

The molecule also influences cellular energy pathways by promoting the uptake and utilization of glucose and oxygen by neurons. By modulating key metabolic enzymes and interacting with pathways involved in oxidative stress, Nicergoline contributes to the stabilization of cellular function and increases neuronal tolerance to metabolic demands. This neuroprotective mechanism increases energy availability for neuronal processes.

Modulation of Neurotransmitter Dynamics

Finally, Nicergoline engages in neurotransmitter modulation by facilitating the release and turnover of key signaling molecules, such as acetylcholine ( ACh), in central synapses. This presynaptic action influences the quality of synaptic communication within neural networks. This modulation of neurotransmitter dynamics influences signal transmission in neural circuits.

How to Use Nicergolina LPH

The administration of the active substance Nicergoline involves established parameters detailing the route, dosage, frequency, and preparation.

---

Administration Scope

Parameter	Official Instruction Details
Route of Administration	The medicine is approved for oral use (tablets/capsules) for chronic management, and parenteral routes, including Intramuscular (IM), Intravenous (IV), and Intra-arterial (IA), for acute supervised use.
Standard Dosing Schedule	The typical daily oral dose for adults is 30 mg, administered in divided doses. Parenteral doses usually range from 4 mg to 8 mg per administration.
Frequency Pattern	Oral therapy is usually administered in three equally divided doses throughout the day. IM injections may be administered up to twice daily.
Timing & Preparation	Oral doses are often recommended to be taken before meals. For IV administration, the solution requires dilution in 0.9% sodium chloride solution or 5%-10% dextrose solution.
Course Duration	The standard course of treatment requires a minimum duration of three months before the therapeutic outcome can be fully evaluated.

---

Special Procedural Conditions

Established protocols require specific dose modifications for certain populations. Patients with impaired kidney (renal) function receive lower therapeutic doses to account for altered elimination. Additionally, administration in patients under 18 years of age is not recommended, as efficacy and safety are not established in this population. If an oral dose is missed, standard practice involves skipping the missed dose and returning to the regular schedule if it is near the time for the next dose, specifically to avoid taking a double dose. The parenteral routes are exclusively intended for use by qualified healthcare professionals in a supervised clinical setting.

Research evidence / Overview of studies for Nicergolina LPH

Evidence for Use in Chronic Cognitive and Neurosensorial Impairment

Nicergoline was evaluated in research settings for its application in conditions related to memory and thinking, especially those associated with aging or reduced blood flow. The evidence relies on Randomized Controlled Trials and systematic reviews that examined older adults with mild to moderate cognitive changes. Researchers monitored outcomes related to daily functioning and standardized cognitive rating scales. Studies report how symptoms evolved in the observed populations, noting differences in cognitive performance.

However, a key limitation noted by regulatory bodies is that the available data provided limited findings related to outcomes, which was considered insufficient for chronic use in some contexts.

Evidence for Peripheral and Oto-Vestibular Circulatory Disorders

Nicergoline was studied for conditions involving heightened symptoms related to blood flow in the periphery and inner ear. This included research on symptoms like Intermittent Claudication (pain during walking) and systemic imbalances such as vertigo or balance problems. For balance issues, studies monitored patient-reported outcomes describing discomfort and symptom severity.

For peripheral vascular issues, the evidence base is older and comprises smaller-scale studies. Regulatory reviews concluded that the limited findings related to outcomes provided insufficient information for these specific indications due to restricted follow-up durations and modest sample sizes.

Study Durations and General Research Limitations

Most core efficacy trials related to cognitive function used observation periods lasting between 3 to 12 months. The long-term effects are not fully established, and there is limited information for outcomes beyond these initial study periods. Furthermore, research primarily examined older adults, and data for specific comorbid or vulnerable populations remain insufficient. This regulatory context underscores the need for ongoing research and emphasizes that certainty remains low for chronic use in several original indications.

Key Studies & References

1. Nicergoline (INN) - WHO ATC Code C04AE02: Peripheral vasodilators, alpha-adrenoreceptor antagonists

Common questions about Nicergolina LPH (FAQ)

---

Q: How quickly should I feel the effects of Nicergolina LPH?

A: Official clinical literature indicates that initial measurable effects on brain function, such as improved alertness or information processing, may be detectable after about 4 to 8 weeks of regular treatment. Regulatory documents state that a therapeutic outcome is typically assessed after a minimum duration of three months of treatment.

---

Q: What is the main benefit of taking Nicergolina LPH?

A: The primary therapeutic purpose is to improve microcirculation and support the metabolic health of tissues, particularly in the brain. The medicine achieves this by increasing cerebral blood flow and enhancing the brain’s ability to use oxygen and glucose.

---

Q: Does Nicergolina LPH improve memory?

A: Official studies indicate that Nicergoline is used in patients experiencing mild to moderate cognitive changes often associated with aging. Clinical trials examining the medicine have observed associations with improvements in measures of cognition and behavior.

---

Q: Can Nicergolina LPH help with dizziness or vertigo?

A: Yes, official product information and studies confirm that Nicergoline has been evaluated for conditions involving impaired blood flow to the inner ear, including vertigo (dizziness) and balance disorders. The medicine is studied for its use in these conditions.

---

Q: Is it normal to feel slightly flushed after taking Nicergolina LPH?

A: Yes, regulatory documents list hot flushes or warmth in the face as common or typical adverse reactions. These effects are usually mild and transient.

---

Q: What should I do if the side effects of Nicergolina LPH are bothersome?

A: Regulatory guidance advises that patients should consult a healthcare professional if they experience bothersome or persistent side effects. Patients are also advised to report any signs of serious reactions, such as those related to fibrosis (unusual tissue growth).

---

Q: Does Nicergolina LPH interact with herbal supplements like Ginkgo Biloba?

A: Due to its intrinsic antiplatelet properties (meaning it affects blood clotting), Nicergolina LPH may increase the risk of bleeding when taken with other agents that also thin the blood. Patients are advised to inform their prescribing doctor about all medicinal products, including herbal supplements like Ginkgo Biloba, which may affect blood clotting.

---

Q: Can Nicergolina LPH make you feel tired or drowsy?

A: Official product information lists side effects that may include general fatigue and central nervous system effects such as dizziness or sleep disturbance. Regulatory guidelines caution against driving or operating machinery if a patient experiences dizziness or drowsiness.

---

Q: Does Nicergolina LPH have any effect on sleep patterns?

A: Yes, official regulatory documents list sleep disturbance as one of the possible side effects associated with Nicergoline.

---

Q: Should Nicergolina LPH be taken with food?

A: Oral doses are commonly recommended to be taken before meals. However, the instructions may permit taking the medicine during meals if stomach discomfort is experienced.

---

Q: What happens if I forget to take a dose of Nicergolina LPH?

A: Official guidance advises that a missed dose should be skipped if it is near the time for the next dose. It is specifically advised to avoid taking a double dose to compensate.

---

Q: Are there different strengths of Nicergolina LPH tablets available?

A: Nicergoline is generally available in various tablet or capsule forms. While the typical daily oral dose for adults is 30 mg in divided doses, different strengths, such as 10 mg and 30 mg tablets, are common.

---

Q: What are the signs that Nicergolina LPH is actually working?

A: In clinical trials, efficacy was assessed by monitoring patient-reported outcomes such as improvements in dizziness, balance, or severity of symptoms. Standardized cognitive rating scales were also used to measure changes in thinking and memory.

---

Q: Is Nicergolina LPH considered a long-term treatment?

A: Regulatory reviews note that the long-term effects of Nicergoline are not fully established. Due to the class risk of serious fibrotic reactions associated with long duration of treatment, the duration of treatment requires regular review due to the risks associated with the drug class.

---

Q: Does Nicergolina LPH have any known drug-food interactions?

A: Regulatory documents advise caution regarding the combination of Nicergolina LPH with alcohol due to the potential for enhanced central nervous system effects, such as dizziness. There is also information suggesting that food might influence the rate at which the medicine is absorbed.

---

Q: Has Nicergolina LPH been studied in clinical trials?

A: Yes, the active substance Nicergoline has been extensively evaluated in various research settings. This includes evidence from Randomized Controlled Trials and systematic reviews concerning its effects on memory, cognitive function, and blood flow.

---

Q: What are the ingredients in Nicergolina LPH besides the active drug?

A: Nicergolina LPH contains the active ingredient Nicergoline. The full list of excipients (inactive ingredients) used to formulate the tablets or solution is detailed in the manufacturer's official Summary of Product Characteristics (SmPC) document.

---

Q: Does Nicergolina LPH require regular monitoring by a doctor?

A: Yes, official warnings and precautions require that patients be monitored for signs of fibrotic disease (excessive tissue formation), particularly if treatment is prolonged. This monitoring is required as a precaution due to the risks associated with medicines in the ergot derivative class.

---

Q: Is it safe to drive while taking Nicergolina LPH?

A: Official information warns that this medicine may cause side effects like dizziness or vertigo. If these symptoms occur, patients are advised to refrain from driving or operating machinery.

---

Q: Does Nicergolina LPH affect liver function?

A: Nicergoline is metabolized (processed) in the liver by the Cytochrome P450 (CYP) enzyme system. Regulatory notes indicate that individuals with impaired liver function may require special consideration or a dose adjustment.

---

Q: Are there any warnings about combining Nicergolina LPH with alcohol?

A: Official product information notes that caution is necessary when combining Nicergolina LPH with alcohol. This is because alcohol can enhance the medicine's effects on the central nervous system, potentially increasing side effects like dizziness.

---

Q: Is Nicergolina LPH used outside of Europe?

A: The active substance Nicergoline has been a clinically recognized ergot derivative for many years. Published literature indicates that the active substance Nicergoline is used in over fifty countries worldwide.

---

Q: Do I need to stop taking other medications before starting Nicergolina LPH?

A: Patients are always advised to inform their prescribing doctor of all current medications being taken. This is important because co-administration with other medicines, such as blood thinners or treatments for high blood pressure, may require dose adjustments to avoid potential interactions.

---

Q: Is it true that Nicergolina LPH can help with symptoms of Raynaud's phenomenon?

A: Official research and indications confirm that Nicergoline is studied and used for conditions caused by poor circulation in the extremities. This includes peripheral vascular disease and symptoms related to vasospasm, such as those seen in Raynaud's disease.

---

Q: What's the meaning of 'LPH' in Nicergolina LPH?

A: The 'LPH' designation is part of the specific trade or brand name of the product. It indicates a particular manufactured preparation that contains the active molecule, Nicergoline.

---

Q: Is Nicergolina LPH a nootropic?

A: While its official regulatory classification is an Adrenergic Alpha-Antagonist and a Peripheral Vasodilator, the medicine is also clinically recognized for its dual role as a supportive nootropic agent. This recognition is due to its documented positive effects on cerebral metabolism and blood flow.

How to Store and Dispose of Nicergolina LPH

Official regulatory guidelines define specific conditions to maintain the stability and safety of Nicergolina LPH.

Storage Requirements

Condition	Requirement
Temperature	Store at room temperature.
Protection	Protect from direct sunlight and keep away from heat, sparks, and flames.
Container	Keep the container tightly sealed/closed and properly labeled to prevent moisture exposure.
Child Safety	Must be stored out of the sight and reach of children.

---

Disposal Instructions

Disposal of unused or expired Nicergolina LPH and its container must comply with all applicable local, regional, and national regulations for pharmaceutical waste. Environmental precautions require that the product be kept away from drains, water courses, and soil to prevent environmental contamination.